Vivacta Biotechnology

formerly Vivacta Bio

Vivacta Biotechnology is a biotech company in Shanghai, United States, founded in 2025. It has raised $50.0M across 2 rounds, most recently an Extension Round in April 2026.

Pioneering in vivo CAR-T cell therapy.

Headquarters
Shanghai
Employees
51–200
Founded
2025
Business Model
B2B
Total Funding
$50.0M
Last Round
Extension RoundApr 2026
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 6 investors for this company. The full record is or through the API.

About

Vivacta Biotechnology is a biotech company developing in vivo CAR-T cell therapies using a T-cell-targeting LNP delivery system. Founded in Shanghai in June 2025, the company focuses on treatments for hematologic malignancies and autoimmune diseases, enabling CAR expression directly within patient T cells without traditional cell isolation procedures.

Summary

It lists 51–200 employees. It has raised $50.0M in total across 2 rounds, most recently a Extension Round in Apr 2026. Investors include Decheng Capital, OrbiMed and Qiming VP.

Tech & App Stack

1 technology or app tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
Extension RoundExtension RoundApr 2026

Sign up to see all 2 events

Funding: Extension Round through Series A. Amounts, valuations, and investors where available.

Investors

Similar Companies

Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Healthcare
Venture RoundTotal funding$884.0MJul 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Vivacta Biotechnology on Indexed.vc
<a href="https://indexed.vc/companies/vivacta-biotechnology"><img src="https://indexed.vc/api/badge/company/vivacta-biotechnology" alt="Vivacta Biotechnology on Indexed.vc" width="260" height="76" /></a>